Overall survival for CLL patients receiving concurrent or sequential treatment.

Overall survival for 51 patients with CLL treated with a concurrent fludarabine and rituximab regimen (unbroken line) and 53 similar patients treated with a sequential fludarabine and rituximab regimen (dashed line) on CALGB 9712. Six patients on the concurrent arm have died, and 2 patients on the sequential arm have died.